黄连温胆汤治疗慢性乙型肝炎肝纤维化肝胆湿热证的效果观察

谢爱泽; 毛德文; 石清兰; 吕超; 柏文婕

doi:10.3969/j.issn.1001-5256.2020.07.012

黄连温胆汤治疗慢性乙型肝炎肝纤维化肝胆湿热证的效果观察

DOI: 10.3969/j.issn.1001-5256.2020.07.012

1. 广西医科大学第一附属医院
2. 广西中医药大学第一附属医院
3. 广西中医药大学

基金项目:

国家自然科学基金地区基金项目(81760849)；

详细信息

中图分类号: R512.62;R575.2
计量
- 文章访问数: 1615
- HTML全文浏览量: 67
- PDF下载量: 161
- 被引次数: 0
出版历程
- 出版日期: 2020-07-20

Clinical effect of Huanglian Wendan decoction in treatment of chronic hepatitis B liver fibrosis patients with liver-gallbladder damp-heat syndrome

1. The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
2. The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China
3. Guangxi University of Chinese Medicine, Nanning 530222, China

Research funding:

摘要

摘要: 目的探讨黄连温胆汤治疗慢性乙型肝炎肝纤维化肝胆湿热证患者的效果及对辅助性T淋巴细胞17（Th17）/IL-17炎症轴的调控作用。方法收集2016年1月-2018年12月在广西中医药大学第一附属医院肝病科诊治的128例肝胆湿热证的慢性乙型肝炎肝纤维化患者的临床资料。以随机数字表法分为治疗组（n=64）和对照组（n=64）,2组均给予核苷类药物恩替卡韦分散片治疗,对照组给予中药安慰剂,治疗组采取黄连温胆汤内服。2组疗程均为24周。比较2组患者肝胆湿热证症状评分、肝功能、肝纤维化血清指标、肝硬度值（LSM）以及外周血IL-17和Th17细胞水平。计量资料2组间比较采用t检验;同一组内不同时间段比较采用单因素方差分析,进一步两两比较采用LSD-t检验;计数资料2组间比较采用χ2检验。结果与同组治疗前比较,对照组和治疗组治疗12、24周后肝胆湿热证症状（胁肋胀痛、身目黄染、小便黄赤、口干苦、舌苔黄腻）评分均显著降低（P值均<0. 01）;2组间治疗12、24周后比较,肝胆湿热证症状评分差异均有统计学意义（P值均<0. 01）。与同组治疗前比较,对照组和治疗组治疗12、24周后肝功能指...
- 乙型肝炎,慢性 /
- 肝硬化 /
- 黄连温胆汤 /
- 肝胆湿热
Abstract: Objective To investigate the clinical effect of Huanglian Wendan decoction in the treatment of chronic hepatitis B liver fibrosis patients with liver-gallbladder damp-heat syndrome and its regulatory effect on T helper 17( Th17) cells/interleukin-17( IL-17) inflammatory axis. Methods A total of 128 chronic hepatitis B liver fibrosis patients with liver-gallbladder damp-heat syndrome who were diagnosed and treated in The First Affiliated Hospital of Guangxi University of Chinese Medicine from January 2016 to December 2018 were enrolled and divided into treatment group and control group using a random number table,with 64 patients in each group. In addition to the treatment with the nucleoside drug entecavir dispersible tablets,the patients in the control group were given the traditional Chinese medicine( TCM) placebo,and those in the treatment group were given oral administration of Huanglian Wendan decoction. The course of treatment was 24 weeks for both groups. The two groups were compared in terms of symptom score of liver-gallbladder damp-heat syndrome,liver function,serological parameters for liver fibrosis,liver stiffness measurement( LSM),and levels of IL-17 and Th17 cells in peripheral blood. The t-test was used for comparison of continuous data between two groups; a one-way analysis of variance was used for comparison within each group at different time points,and the least significant difference t-test was used for further comparison between two time points. The chi-square test was used for comparison of categorical data between two groups. Results After 12 and 24 weeks of treatment,both groups had significant reductions in the scores of the symptoms of liver-gallbladder damp-heat syndrome( distending pain in the hypochondrium,jaundice of the skin and eyes,deep-colored urine,dry mouth and bitter taste,and slimy yellow tongue fur)( all P < 0. 01),and there were significant differences in the scores of the symptoms of liver-gallbladder damp-heat syndrome between the two groups( all P < 0. 01). After 12 and 24 weeks of treatment,both groups had significant reductions in the liver function parameters aspartate aminotransferase,alanine aminotransferase,total bilirubin,and gamma-glutamyl transpeptidase( all P < 0. 01),and there were significant differences in these liver function parameters between the two groups( all P < 0. 01). After 12 and 24 weeks of treatment,both groups had significant reductions in serological parameters for liver fibrosis( hyaluronic acid,procollagen type Ⅲ,type Ⅳ collagen,and laminin) and LSM( all P < 0. 01),and there were significant differences in these serological parameters for liver fibrosis and LSM between the two groups( both P < 0. 01). After 24 weeks of treatment,the treatment group had significant reductions in the count of Th17 cells and the level of IL-17 in peripheral blood( t = 2. 79 and 2. 60,both P < 0. 01),and the control group had a significant reduction in the count of Th17 cells in peripheral blood( t = 2. 47,P < 0. 01); after 24 weeks of treatment,the treatment grop had significantly lower count of Th17 cells and level of IL-17 in peripheral blood than the control group( both P < 0. 01). There was a significant difference in overall response rate between the control group and the treatment group( 76. 56% vs 90. 63%,χ2= 4. 61,P < 0. 05). Conclusion On the basis of antiviral therapy with nucleosides in Western medicine,Huanglian Wendan decoction has a marked clinical effect in the treatment of chronic hepatitis B liver fibrosis patients with liver-gallbladder damp-heat syndrome,possibly by regulating the Th17/IL-17 inflammatory axis.
- hepatitis B chronic /
- liver cirrhosis /
- Huanglian Wendan Decoction /
- liver gallblad damp heat

HTML全文

参考文献(16)

[1]WU QM,YOU H.Hepatitis B-related liver cirrhosis:Research updates in China[J].Chin J Viral Dis,2014,4(1):7-10.(in Chinese)吴钦梅，尤红．中国乙型病毒性肝炎肝硬化研究现状[J]．中国病毒病杂志，2014,4(1):7-10．

[2]FANG RQ,SU CZ,ZHU GJ,et al.Therapeutic efficacy of entecavir combined with Fuzheng Huayu capsule in 73 cases of liver fibrosis in chronic hepatitis B[J].Chin J Gastroenterol Hepatol,2013,22(1):31-33.(in Chinese)范瑞琴，苏传真，朱刚剑，等．恩替卡韦联合扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化73例疗效观察[J]．胃肠病学和肝病学杂志，2013,22(1):31-33．

[3]ZENG J,ZHANG L,LI J,et al.Curative effect and quality of life of chronic hepatitis B patients with liver fibrosis with syndromes of liver depression,spleen deficiency and blood stasis obstruction treated with ruangan huaxian decoction combined with entecavir[J].Chin J Exp Med Formul,2017,23(11):177-183.(in Chinese)曾健，张玲，李军，等．软肝化纤汤联合恩替卡韦治疗肝郁脾虚并瘀血阻络型慢性乙型肝炎肝纤维化患者临床疗效和生活质量观察[J]．中国实验方剂学杂志，2017,23(11):177-183．

[4]YANG LS,FAN JW,LIANG ZQ,et al.Chronic hepatitis B TCMsyndrome classification and the relationship between peripheral blood lymphocyte subsets[J].Chin J Basic Med Tradit Chin Med,2017,23(5):669-671.(in Chinese)杨丽莎，范剑薇，梁志清，等．慢性乙型肝炎证候虚实分类与外周血淋巴细胞亚群的关系[J]．中国中医基础医学杂志，2017,23(5):669-671．

[5]LIU Z,LI YB,ZHANG WH,et al.Protective effect of Huanglian Wendan decoction on liver damage in rat model of type 2 diabetic mellitus[J].Mod J Integr Tradit Chin West Med,2016,25(2):119-121,151.(in Chinese)刘舟，李月碧，张卫华，等．黄连温胆汤对2型糖尿病大鼠肝损伤的保护作用[J]．现代中西医结合杂志，2016,25(2):119-121,151．

[6]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1941-1960．

[7]Liver Disease Committee,Chinese Association of Integrative Medicine.Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice[J/CD].Chin J Liver Dis(Electr Version),2010,2(4):54-59.(in Chinese)中国中西医结合学会肝病专业委员会．肝纤维化中西医结合诊疗指南[J/CD]．中国肝脏病杂志(电子版)，2010,2(4):54-59．

[8]Hepatobiliary Disease Group,Internal Medicine of Traditional Chinese,China Association of Traditional Chinese Medicine.Guidelines for traditional Chinese medical diagnosis of chronic hepatitis B[J].JClin Hepatol,2012,28(3):164-168.(in Chinese)中华中医药学会内科肝胆病学组，世界中医药联合学会肝病专业委员会，中国中西医结合学会肝病分组．慢性乙型肝炎中医诊疗专家共识[J]．临床肝胆病杂志，2012,28(3):164-168．

[9]Hepatobiliary Specialized Committee of China Association of Chinese Medicine,Liver Diseases Specialized Committee of China Medical Association of Minorities.The clinical guidelines of diagnosis and treatment of chronic hepatitis B with traditional Chinese medicine(2018)[J].J Clin Hepatol,2018,34(12):2520-2525.(in Chinese)中华中医药学会肝胆病专业委员会，中国民族医药学会肝病专业委员会．慢性乙型肝炎中医诊疗指南(2018年版)[J]．临床肝胆病杂志，2018,34(12):2520-2525．

[10]Liver Disease Committee,Chinese Association of Integrative Medicine.Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice(2019)[J].J Clin Hepatol,2019,35(7):1444-1449.(in Chinese)中国中西医结合学会肝病专业委员会．肝纤维化中西医结合诊疗指南(2019年版)[J]．临床肝胆病杂志，2019,35(7):1444-1449．

[11]Liver Fibrochemistry Group of Chinese Society of Hepatology.Consensus on evaluation of the diagnosis and efficacy of hepatic fibrosis[J].Drug Eval,2007,4(4):265-266.(in Chinese)中华肝脏病学会肝纤维化学组．肝纤维化诊断及疗效评估共识[J]．药品评价，2007,4(4):265-266．

[12]LIN TF,WANG SY,LYU MH,et al.Clinical observation on anluohuaxian Pill combined with entecavir in the treatment of damp heat syndrome and liver stagnation and spleen deficiency syndrome of hepatitis B liver fibrosis[J].Clin J Trad Chin Med,2016,28(7):980-983.(in Chinese)林涛发，王少扬，吕美煌，等．安络化纤丸联合恩替卡韦治疗肝郁脾虚型与湿热中阻型乙肝肝纤维化疗效比较[J]．中医药临床杂志，2016,28(7):980-983．

[13]FENG H,ZHANG YH.Effect of Chinese medicine therapy for strengthening-Pi and and nourishing-shen in preventing-Iamivudine induced YMDD mutation and it simmunologic mechanism[J].Chin J Integr Med,2010,16(1):19-22．

[14]YE Y,XIE X,YU J.Involvement of Th17and Th1 effector responses in patients with Hepatitis B[J].J Clin Immunol,2010,30(4):546-555．

[15]TAN NH,CHEN B.Change in the expression of T helper 17 cells/regulatory T cells at the time of intestinal endotoxemia in rats with subacute-on-chronic liver failure:An experimental study[J].Hunan J Tradit Chin Med,2019,35(3):134-138.(in Chinese)谭年花，陈斌．慢加亚急性肝衰竭大鼠肠源性内毒素血症时Th17/Treg表达变化的实验研究[J]．湖南中医杂志，2019,35(3):134-138．

[16]SHI QL,MAO DW,CHEN YQ,et al.Effect of JieduⅡDecoction on the expression of Th17 and Th1 in peripheral blood of patients with HBV related acute liver failure and its clinical efficacy[J].China Med Herald,2018,15(21):122-125.(in Chinese)石清兰，毛德文，陈月桥，等．解毒化瘀Ⅱ方对HBV相关急性肝衰竭患者外周血Th17、Th1表达及临床疗效的影响[J]．中国医药导报，2018,15(21):122-125.

施引文献

资源附件(0)

访问统计